Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Condition:   Differentiated Thyroid Carcinoma
Intervention:   Drug: Apatinib Mesylate
Sponsor:   Tianjin Medical University Cancer Institute and Hospital
Recruiting - verified March 2017

http://ift.tt/2rkFgIO


http://ift.tt/2rkt0rF